Cyclophosphamide, bortezomib and dexamethasone (CyBorD) is a highly active three-drug induction regimen for untreated transplant-eligible multiple myeloma patients. Although CyBorD has been evaluated ...

Funding to accelerate continued adoption of Visual AI among leading global electronics OEMs TEL AVIV, Israel, April 28, 2026 /PRNewswire/ -- Cybord AI, a leader in Visual AI for electronic component ...

WILMINGTON, Del., March 11, 2025 /PRNewswire/ -- Cybord, the leading provider of advanced AI-powered electronic component analytics, today announced the launch of its Real-Time Interception (RTI) ...

Leveraging AI and big data, Cybord analyzes 100% of electronic components on the assembly line, verifying their reliability, authenticity, and traceability to support all industries utilizing ...

TEL AVIV, Israel, Sept. 17, 2025 /PRNewswire/ -- Cybord, a leading provider of advanced visual-AI electronic component analytics solutions, today announced the launch of its fully air-gapped platform, ...

Patients with newly diagnosed light chain (AL) amyloidosis could soon have a new treatment option: daratumumab (Darzalex, Janssen) along with the standard treatment used in these patients ― the ...

TEL AVIV, Israel, April 3, 2023 /PRNewswire/ -- Cybord, the leading inline visual AI electronic component analytics software, today announced the appointment of Marc Sultzbaugh to the Cybord Board of ...

Cybord has announced its collaboration with Siemens. Cybord, a leading provider of advanced visual-AI electronic component analytics, and Siemens Digital Industries Software have signed a new OEM ...

Electronic components are the base for all electronic circuit boards. Their authenticity, quality, and reliability are at the core of electronic performance. The sophisticated electronics industry ...

Patients have been dealt a major blow after the first ever treatment for AL amyloidosis, a rare incurable condition, was rejected by the National Institute for Health and Care Excellence (NICE). This ...